Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/18/15 → 7/23/20 |
Funding
- Atox Bio: $202,614.00
Phase III, randomized, double-blind, placebo-controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI)
- Bernard, Andrew (PI)